Lead Sponsor

GlaxoSmithKline

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•HIV-infected.
•Screening viral load at least 5000copies/mL.
•X4-tropic only or non-phenotypeable virus at screening.
•Total prior antiretroviral experience of at least 3 months and documented resistance to at least one drug in each of the following classes: NRTI, NNRTI, and PI, stable antiretroviral regimen (or no antiretroviral treatment) for at least 4 weeks before screening.
•Able to receive a ritonavir-boosted protease inhibitor during treatment studies.
•Women of childbearing potential must use specific forms of contraception.

•R5-tropic only or R5/X4-tropic virus at screening, changes to antiretroviral therapy from 4 weeks prior to screening until Day 1 of observational study.
•Pregnant or breastfeeding women.
•Significant ECG abnormalities or significant history of active pancreatitis, hepatitis, opportunistic infections, cancer, or severe illness.
•Current use of certain medications may exclude participation in this study.
•Additional qualifying criteria and laboratory test requirements to be determined by study physician.

Related studies

NCT06857071 · Undiagnosed HIV Infection, Populations That Are Reluctant to Test for HIV, and more

NCT06627764 · Substance Abuse, Intimate Partner Violence (IPV), and more

NCT06900829 · HIV Infection, HIV, and more

NCT04142047 · HIV, HIV Infections

NCT06694805 · HIV Infections

Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus